Go Pro
Keay Nakae

Keay Nakae Analyst Performance

Senior Research Analyst, Small RNA, Microbiome, Digital Therapeutics at Chardan Capital

Keay Nakae is a stock analyst at Chardan Capital focused in the healthcare sector, covering 39 publicly traded companies. Over the past year, Keay Nakae has issued 63 stock ratings, including buy and hold recommendations. While full access to Keay Nakae's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Keay Nakae's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
190 Last 10 Years
Buy Recommendations
92.51% 173 Buy Ratings
Companies Covered
39 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy92.5%173 ratings
Hold7.0%13 ratings
Sell0.5%0 ratings

Out of 187 total stock ratings issued by Keay Nakae at Chardan Capital, the majority (92.5%) have been Buy recommendations, followed by 7.0% Hold and 0.5% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
89.7% of companies on NASDAQ
35 companies
NYSE
7.7% of companies on NYSE
3 companies
NYSEAMERICAN
2.6% of companies on NYSEAMERICAN
1 company

Keay Nakae, an analyst at Chardan Capital, currently covers 39 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
36 companies
92.3%
Technology
2 companies
5.1%
Miscellaneous
1 company
2.6%

Keay Nakae of Chardan Capital specializes in stock coverage within the Healthcare sector, with additional focus on Technology and companies.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
29 companies
74.4%
PHARMACEUTICALS
3 companies
7.7%
HEALTHCARE EQUIPMENT & SUPPLIES
3 companies
7.7%
SOFTWARE
2 companies
5.1%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
2.6%
Miscellaneous
1 company
2.6%

About Keay Nakae

Keay Nakae is a Senior Research Analyst at Chardan. Mr. Nakae has over 17 years of experience as a sell-side research analyst covering healthcare companies, and has previously worked at Wedbush Morgan, and CE Unterberg Towbin/Collins Stewart. Mr. Nakae has made numerous media appearances on Bloomberg TV, and has been quoted in publications such as The Wall Street Journal, Time, Business Week, and The Los Angeles Times. He has been recognized by Forbes magazine in its annual survey of America’s Best Analysts. Mr. Nakae earned an MBA degree from UCLA’s Anderson School of Management, and holds MS and BS degrees in electronic engineering from Cal Poly. Mr. Nakae is a CFA charterholder and a member of the CFA Institute.
Follow on LinkedIn

Keay Nakae's Ratings History at Chardan Capital

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
8/25/2026Initiated Coverage$3.25$7.00Buy
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
8/25/2026Initiated Coverage$3.58$7.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
8/12/2026Reiterated Rating$4.80$14.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
8/4/2026Reiterated Rating$29.56$35.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
7/31/2026Reiterated Rating$205.48$425.00Buy
Promis Neurosciences stock logo
PMN
Promis Neurosciences
7/27/2026Set Price Target$12.20$20.00Buy
Promis Neurosciences stock logo
PMN
Promis Neurosciences
7/27/2026Initiated Coverage$14.52$20.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
7/22/2026Boost Price Target$89.36$115.00Buy
Metagenomi, Inc. stock logo
MGX
Metagenomi
7/7/2026Initiated Coverage$1.25$5.00Buy
iBio, Inc. stock logo
IBIO
iBio
7/2/2026Reiterated Rating$1.75$5.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
6/30/2026Reiterated Rating$80.50$90.00Buy
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
6/26/2026Lower Price Target$1.57$3.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
6/17/2026Boost Price Target$3.66$16.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
6/12/2026Reiterated Rating$4.89$14.00Buy
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
6/10/2026Set Price Target$4.01$6.50Buy
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
6/10/2026Initiated Coverage$4.34$6.50Buy
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
4/22/2026Reiterated Rating$27.13$30.00Buy
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
4/9/2026Reiterated Rating$1.83$4.00Buy
iBio, Inc. stock logo
IBIO
iBio
4/9/2026Reiterated Rating$2.24$5.00Buy
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
4/2/2026Reiterated Rating$23.38$30.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
3/30/2026Reiterated Rating$54.10$100.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
3/25/2026Reiterated Rating$326.30$425.00Buy
iBio, Inc. stock logo
IBIO
iBio
3/18/2026Reiterated Rating$2.46$5.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3/18/2026Reiterated Rating$32.87$35.00Buy
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
3/17/2026Reiterated Rating$24.27$30.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
3/16/2026Reiterated Rating$4.47$14.00Buy
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
3/12/2026Reiterated Rating$4.38$20.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
3/11/2026Boost Price Target$4.54$14.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3/9/2026Reiterated Rating$17.64$38.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3/2/2026Reiterated Rating$16.15$38.00Buy
Allurion Technologies, Inc. stock logo
ALUR
Allurion Technologies
2/24/2026Set Price Target$26.21$45.00Buy
Allurion Technologies, Inc. stock logo
ALUR
Allurion Technologies
2/24/2026Set Price Target$18.23$45.00
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2/13/2026Lower Price Target$308.48$425.00Buy
iBio, Inc. stock logo
IBIO
iBio
2/12/2026Reiterated Rating$2.21$5.00Buy
Korro Bio, Inc. stock logo
KRRO
Korro Bio
1/29/2026Upgrade$11.69$15.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1/29/2026Reiterated Rating$67.43$100.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
1/8/2026Reiterated Rating$5.12$14.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
1/7/2026Boost Price Target$70.81$80.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
1/5/2026Set Price Target$30.90$35.00
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
1/5/2026Reiterated Rating$6.20$40.00Buy
The dollar reset no one told you about (Ad)

Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.tc pixel

Read the full briefing and see how to position yourself now
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
1/5/2026Boost Price Target$30.90$35.00Buy
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
1/5/2026Boost Price Target$16.61$30.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
12/18/2025Reiterated Rating$3.96$12.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
12/9/2025Reiterated Rating$22.20$38.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
12/1/2025Reiterated Rating$52.78$60.00Buy
Allurion Technologies, Inc. stock logo
ALUR
Allurion Technologies
11/20/2025Reiterated Rating$1.35Neutral
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
11/19/2025Reiterated Rating$40.47$60.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
11/17/2025Reiterated Rating$3.24$12.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
11/14/2025Reiterated Rating$5.96$14.00Buy
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
11/14/2025Reiterated Rating$4.52$5.00Buy
Korro Bio, Inc. stock logo
KRRO
Korro Bio
11/13/2025Reiterated Rating$31.42Neutral
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
11/13/2025Reiterated Rating$4.42$20.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
11/11/2025Reiterated Rating$69.84$72.00Neutral
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
11/9/2025Boost Price Target$80.95$100.00Buy
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
11/4/2025Reiterated Rating$2.59$4.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
10/28/2025Reiterated Rating$70.00$72.00Neutral
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
10/28/2025Set Price Target$70.00$72.00
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
10/28/2025Downgrade$69.93$72.00Hold
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
9/25/2025Boost Price Target$73.04$85.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
9/19/2025Reiterated Rating$2.38$12.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
9/17/2025Reiterated Rating$5.67$14.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
9/16/2025Reiterated Rating$54.49$60.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
9/10/2025Reiterated Rating$47.34$75.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
8/13/2025Reiterated Rating$6.02$14.00Buy
Korro Bio, Inc. stock logo
KRRO
Korro Bio
8/13/2025Reiterated Rating$18.93$25.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
8/13/2025Reiterated Rating$33.51$60.00Buy
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
8/13/2025Reiterated Rating$2.66$20.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
8/11/2025Reiterated Rating$16.42$60.00Buy
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
8/11/2025Reiterated Rating$3.40$5.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
8/8/2025Lower Price Target$2.23$12.00Buy
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
8/8/2025Reiterated Rating$5.38$35.00Buy
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
8/8/2025Reiterated Rating$2.05$4.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
8/8/2025Reiterated Rating$47.52$75.00Buy
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
8/7/2025Reiterated Rating$2.64$20.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
8/1/2025Boost Price Target$392.24$400.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
7/29/2025Lower Price Target$9.31$38.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
7/1/2025Reiterated Rating$5.72$14.00Buy
iBio, Inc. stock logo
IBIO
iBio
6/25/2025Reiterated Rating$0.75$5.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
6/23/2025Initiated Coverage$32.86$60.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
6/17/2025Reiterated Rating$11.48$50.00Buy
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
6/13/2025Reiterated Rating$5.59$35.00Buy
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
6/9/2025Boost Price Target$33.13$75.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
5/15/2025Reiterated Rating$2.01$20.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
5/13/2025Reiterated Rating$13.97$60.00Buy
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
5/13/2025Reiterated Rating$2.94$20.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
5/13/2025Reiterated Rating$5.76$14.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
5/9/2025Reiterated Rating$11.32$50.00Buy
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
5/9/2025Lower Price Target$3.56$35.00Buy
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
5/8/2025Reiterated Rating$8.29$6.00Neutral
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
5/7/2025Reiterated Rating$26.26$65.00Buy
The cat is out the bag (Ad)

Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel

Watch Porter Stansberry's full investigation into the Final Displacement now
iBio, Inc. stock logo
IBIO
iBio
5/5/2025Reiterated Rating$1.01$5.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
5/2/2025Boost Price Target$255.13$325.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
4/28/2025Reiterated Rating$6.18$14.00Buy
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
4/22/2025Reiterated Rating$2.90$20.00Buy
Korro Bio, Inc. stock logo
KRRO
Korro Bio
4/16/2025Initiated Coverage$13.40$25.00Buy
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
4/7/2025Reiterated Rating$1.25$20.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
4/1/2025Lower Price Target$1.40$20.00Buy
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
4/1/2025Reiterated Rating$3.24$20.00Buy
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
3/28/2025Reiterated Rating$2.07$6.00Buy
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
3/28/2025Reiterated Rating$3.27$5.00Buy
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
3/28/2025Reiterated Rating$1.31$20.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
3/21/2025Reiterated Rating$253.60$300.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
3/20/2025Reiterated Rating$6.45$14.00Buy
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3/20/2025Reiterated Rating$14.64$25.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3/17/2025Reiterated Rating$12.22$50.00Buy
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
3/14/2025Reiterated Rating$1.74$4.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2/28/2025Reiterated Rating$13.30$50.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2/26/2025Reiterated Rating$245.20$300.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2/11/2025Reiterated Rating$19.92$60.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
2/6/2025Reiterated Rating$7.00$14.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
1/29/2025Reiterated Rating$2.28$25.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
1/10/2025Reiterated Rating$15.46$50.00Buy